Israeli biopharmaceutical firm Mileutis said on Tuesday results from a clinical trial showed that its non-antibiotic substitute to treat infections in cows boosted milk quality

Mileutis, an innovative biopharmaceutical firm based in Israel and focused on reforming the way farmers and veterinarians address a variety of diseases, announced that its

Three new appointments bring a wealth of experience as the organization continues its commitment to revolutionizing biopharmaceuticals to improve global animal health Mileutis, an Israeli-based

Mileutis has developed a biological preparation for the treatment of inflammation, with the goal of removing antibiotics from dairy products.

Leading journal of dairy sciences recently publishes a study that presents a case for antibiotic alternatives to treat cows at dry-off The study shows high

NESS ZIONA, Israel, Jan. 18, 2022 /PRNewswire/  Mileutis, an Israeli-based biopharmaceutical company revolutionizing how farmers and veterinarians treat a range of diseases, today announced the appointment of two new

“Some 70% of antibiotics worldwide are administered to animals, and affected pathogens may later develop antimicrobial resistance and enter the environment, affecting humans,” says David

David Javier Iscovich, Mileutis ceo, In an interview for the Animal Health Innovation Europe conference 2021

Mileutis was selected as an emerging company back in 2016 at the very first Animal Health Innovation Europe event. CEO of Mileutis, David Javier Iscovich,

Mileutis is developing residue-free natural proteins based on early research conducted at Israel’s Agricultural Research Organization (Volcani Center), and at Mileutis. The company is developing

NESS ZIONA, Israel /PRNewswire/ Antimicrobial resistance (AMR), which is mainly caused by antibiotic use, is one of the top 10 global public health threats facing

Raleigh, North Carolina and Ness Ziona, Israel – NovaQuest Capital Management LLC, a leading investor in life sciences and healthcare, announced a $20 million (USD)